Saltz LB - Search Results

1

Phase II Study of First-Line Trebananib Plus Sorafenib in Patients with Advanced Hepatocellular Carcinoma.

Abou-Alfa GK, Blanc JF, Miles S, Ganten T, Trojan J, Cebon J, Liem AK, Lipton L, Gupta C, Wu B, Bass M, Hollywood E, Ma J, Bradley M, Litten J, Saltz LB. Abou-Alfa GK, et al. Among authors: saltz lb. Oncologist. 2017 Jul;22(7):780-e65. doi: 10.1634/theoncologist.2017-0058. Epub 2017 Jun 7. Oncologist. 2017. PMID: 28592620 Free PMC article. Clinical Trial.

2

Phase I clinical and pharmacologic study of weekly cisplatin combined with weekly irinotecan in patients with advanced solid tumors.

Saltz LB, Spriggs D, Schaaf LJ, Schwartz GK, Ilson D, Kemeny N, Kanowitz J, Steger C, Eng M, Albanese P, Semple D, Hanover CK, Elfring GL, Miller LL, Kelsen D. Saltz LB, et al. J Clin Oncol. 1998 Dec;16(12):3858-65. doi: 10.1200/JCO.1998.16.12.3858. J Clin Oncol. 1998. PMID: 9850031 Clinical Trial.

3

A phase II trial of interferon alpha-2a and carboplatin in patients with advanced malignant mesothelioma.

O'Reilly EM, Ilson DH, Saltz LB, Heelan R, Martin L, Kelsen DP. O'Reilly EM, et al. Among authors: saltz lb. Cancer Invest. 1999;17(3):195-200. doi: 10.3109/07357909909021421. Cancer Invest. 1999. PMID: 10099658 Clinical Trial.

4

Phase II clinical trial of 13-cis-retinoic acid and interferon-alpha-2a in patients with advanced esophageal carcinoma.

Enzinger PC, Ilson DH, Saltz LB, Martin LK, Kelsen DP. Enzinger PC, et al. Among authors: saltz lb. Cancer. 1999 Mar 15;85(6):1213-7. doi: 10.1002/(sici)1097-0142(19990315)85:6<1213::aid-cncr1>3.0.co;2-n. Cancer. 1999. PMID: 10189124 Clinical Trial.

5

Failure to confirm major objective antitumor activity for streptozocin and doxorubicin in the treatment of patients with advanced islet cell carcinoma.

Cheng PN, Saltz LB. Cheng PN, et al. Among authors: saltz lb. Cancer. 1999 Sep 15;86(6):944-8. Cancer. 1999. PMID: 10491519

6

Oral chemotherapeutic agents for colorectal cancer.

Sharma S, Saltz LB. Sharma S, et al. Among authors: saltz lb. Oncologist. 2000;5(2):99-107. doi: 10.1634/theoncologist.5-2-99. Oncologist. 2000. PMID: 10794800 Free article. Review.

7

Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group.

Saltz LB, Cox JV, Blanke C, Rosen LS, Fehrenbacher L, Moore MJ, Maroun JA, Ackland SP, Locker PK, Pirotta N, Elfring GL, Miller LL. Saltz LB, et al. N Engl J Med. 2000 Sep 28;343(13):905-14. doi: 10.1056/NEJM200009283431302. N Engl J Med. 2000. PMID: 11006366 Free article. Clinical Trial.

8

A phase II study of irinotecan in patients with advanced hepatocellular carcinoma.

O'Reilly EM, Stuart KE, Sanz-Altamira PM, Schwartz GK, Steger CM, Raeburn L, Kemeny NE, Kelsen DP, Saltz LB. O'Reilly EM, et al. Among authors: saltz lb. Cancer. 2001 Jan 1;91(1):101-5. doi: 10.1002/1097-0142(20010101)91:1<101::aid-cncr13>3.0.co;2-k. Cancer. 2001. PMID: 11148565 Clinical Trial.

9

Irinotecan plus fluorouracil/leucovorin for metastatic colorectal cancer: a new survival standard.

Saltz LB, Douillard JY, Pirotta N, Alakl M, Gruia G, Awad L, Elfring GL, Locker PK, Miller LL. Saltz LB, et al. Oncologist. 2001;6(1):81-91. doi: 10.1634/theoncologist.6-1-81. Oncologist. 2001. PMID: 11161231 Free article. Clinical Trial.

10

Phase I study of topoisomerase I inhibitor exatecan mesylate (DX-8951f) given as weekly 24-hour infusions three of every four weeks.

Sharma S, Kemeny N, Schwartz GK, Kelsen D, O'Reilly E, Ilson D, Coyle J, De Jager RL, Ducharme MP, Kleban S, Hollywood E, Saltz LB. Sharma S, et al. Among authors: saltz lb. Clin Cancer Res. 2001 Dec;7(12):3963-70. Clin Cancer Res. 2001. PMID: 11751488 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

413 results

Search Page